A recommended practical approach to the management of target therapy and angiogenesis inhibitors cardiotoxicity: an opinion paper of the working group on drug cardiotoxicity and cardioprotection, Italian Society of Cardiology

Maurea, Nicola;Spallarossa, Paolo;CADEDDU DESSALVI, CHRISTIAN;Madonna, Rosalinda;Mele, Donato;Monte, Ines;Novo, Giuseppina;PAGLIARO, PASQUALE;Pepe, Alessia;Tocchetti, Carlo G;Zito, Concetta;MERCURO, GIUSEPPE

2016-01-01

---

Abstract

The US National Cancer Institute estimates that cardiotoxicity (CTX) from target therapy refers mostly to four groups of drugs: epidermal growth factor receptor 2 inhibitors, angiogenic inhibitors, directed Abelson murine leukemia viral oncogene homolog inhibitors, and proteasome inhibitors. The main cardiotoxic side-effects related to antiepidermal growth factor receptor 2 therapy are left ventricular systolic dysfunction and heart failure. Angiogenesis inhibitors are associated with hypertension, left ventricular dysfunction/heart failure, myocardial ischemia, QT prolongation, and thrombosis. Moreover, other agents may be related to CTX induced by treatment. In this study, we review the guidelines for a practical approach for the management of CTX in patients under anticancer target therapy